International Stem Cell Corporation Company

EyeCyte is engaged in the development of therapeutics for the treatment of neovascular and degenerative retinal diseases.
EyeCyte, Inc. is working with Pfizer's Bioinnovation and io therapeutics Center and The Scripps Research Institute to develop novel therapeutics to treat neovascular and degenerative retinal disease.
Technology: Stem Cell
Industry: Regenerative medicine
Headquarters: United States
Founded Date: 2001
Employees Number: Undisclosed
Funding Status: IPO
Total Funding: $7.5M
Estimated Revenue: $1M to $10M
Last Funding Type: Post-IPO Equity

Visit Website
ir@intlstemcell.com
http://twitter.com/intlstemcell
Register and Claim Ownership